Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
NOVARTIS NEW ZEALAND LIMITED,Ofatumumab,Relapsing Remitting Multiple Sclerosis (MS),Ofatumumab (KESIMPTA),Only if cost neutral or cost saving,Community and Hospital,Nervous System
